Diabetes, Heart and Cardiovascular Diseases News Chronicle.  Diabetes, Cardiovascular and Heart Diseases
 Article 58
    Published on September 16, 2016


Chronic Kidney Disease, Heart Disease & Diabetes Prevention Drugs From Forxiga Drug Maker AstraZeneca

AstraZeneca is trying to expand usage of its drug Forxiga to treat other diseases such as kidney and heart apart with diabetes. The company planning two trials, one for chronic kidney disease (CKD) and other for chronic heart failure. The company is recruiting patients with or without type 2 diabetes (T2D) patients for clinical trials. The company simultaneously planning trials for SGLT2 inhibitor Forxiga (dapagliflozin) drug.




       
Post a message on social media and mail to your friend and doctor to resolve your health condition. Article address TO LINK on your social media is (copy and paste the code below) :

Articles similar to this topic


1. Risks With Chronic Kidney Disease CKD
2. Diabetic Kidney Disease Statistics
3. Trials With Forxiga (Dapagliflozin), Victoza (Liraglutide) And Insulin Approach (Triple Therapy)
4. Approval Of AstraZeneca's Diabetes Combination
5. Device To Detect Deadly Ketones

 

AstraZeneca : Founded in 1913 in Sweden, AstraZeneca is a multinational biopharmaceutical company having headquarters in Cambridge, UK. Company manufacture medicines for the treatment of diseases such as gastrointestinal, cancer, diabetes, cardiovascular, neuroscience, infection, respiratory and inflammation.

Chronic kidney disease : Kidney function is filtering waste and excess fluids from the blood. Chronic kidney disease (CKD) or chronic renal disease is a gradual deterioration of kidney function over months or years. Waste builds up in the body as kidney fails. This disease won't show symptoms until the disease is serious.

SGLT2 inhibitors : SGLT2 stands for sodium glucose co-transporter 2 prescription drugs for type 2 diabetes and not for type 1 diabetes (T1D). These drugs have FDA approval. They are part of diet and exercise plan to reduce sugar levels. Drugs dapagliflozin (forxiga), canagliflozin (invokana), and empagliflozin (jardiance) come under this classification. Canagliflozin (invokana) is the only drug approved by FDA. Possible side effects of SGLT2 inhibitors are

  • Dehydration
  • Low blood sugar levels
  • Kidney problem
  • Acidosis

 

Mangoes Helps In The Growth Of Gut Bacteria Or Microbiota And Prevents Obesity

Experiments conducted on mice by scientists shows mango fruit prevented loss of bugs, helps the growth of microbiota (also called gut flora, bacteria). Medical community believes that some type of bacteria in our intestinal tract helps us in preventing obesity, type 2 diabetes (T2D) and other health diseases. Mango fruit contains antioxidants, fiber, minerals, vitamins and fat busting plant chemicals. The study was conducted by Prof Edralin Lucas, Oklahoma State University and the study findings were published in the Journal of Nutrition .




       
Post a message on social media and mail to your friend and doctor to resolve your health condition. Article address TO LINK on your social media is (copy and paste the code below) :

Articles similar to this topic


1. Risks With Gut Bacteria Imbalance
2. Role Of Gut Bacteria After Duodenum Jejunum Bypass Surgery
3. Biomarkers To Childhood Obesity
4. Risk With Teenage Obesity
5. Device To Predict Diabetes

 

Microbiota : Also known as gut microbiota or gastrointestinal microbiota. Gut bacteria are microorganisms and they live in digestive tracts (intestine) of humans, animals and insects. Digestive tracks of babies are colonized by microorganisms from the mother and well established in humans by the age of 1 or 2 years. Our gut contains tens of trillions of bacteria with at least 1000 species and weighing at least 2 kgs. They

  • Helps us in producing some type of vitamin B and vitamin K
  • Our stomach and small intestine fail in digesting some type of foods. Microbiota helps us in digesting such foods
  • They play a key role in our immune system

Loss of microbiota balance is called as dysbiosis. Dysbiosis was linked to health problems such as diabetes, allergies, obesity and complications in the bowel. Healthy digestive gut microbiota can be grown by

  • Probiotic supplements
  • Traditional fermented foods
  • Lactic acid yeast wafers

 

About Onduo, A Joint Venture JV Between Verily Alphabet And Sanofi

French multinational pharmaceutical company Sanofi, Gentilly, France and US-based Verily belonging to Alphabet's started Onduo, a joint venture (JV) to provide devices and services to diabetes patients. The new company initially going to focus on products and services to type ii diabetes (T2D) patients but will concentrate on type 1 diabetes (T1D) in future. The new company will be based in Cambridge, near Boston, U.S.




       
Post a message on social media and mail to your friend and doctor to resolve your health condition. Article address TO LINK on your social media is (copy and paste the code below) :

Articles similar to this topic


1. Treatment With Sanofi's LixiLan
2. About Revita DMR Device
3. Device To Release Drugs In Eye
4. Discovery Gene Destroying Insulin-Producing Cells
5. Risk To Insulin Resistance With Air Pollution

 

Verily : Verily, established on Dec 7, 2015, is a research organization in the field of health and independent subsidiary of Alphabet. Inc. Previously Verily was known as Google life Sciences. Company focus on prevention, detection and management of human health diseases. Some of Verily projects are

  • Contact lenses to check glucose levels continuously
  • A wristband to track the health of an individual
  • Partnered with Johnson & Johnson to provide solutions in the field of surgical robotics
  • Partnered with GlaxoSmithKline to provide solutions in the field of bioelectronic medicines

 

 

Site maps

Site map 1   Site map 2   Site map 3   Site map 4


The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. Published article is not a medical advice by the OWNER of "Diabetes News Chronicle" website or by the AUTHOR of the article.


Published by Jammi Vasista, Chennai, India.
Email Jammi[no-space]Vasista1991[at]gmail[dot]com
Phone 91-944-578-3182.
Address Diabetes News Chronicle, No 40, Kaveri Street, Rajaji Nagar, Villivakkam, Chennai, India. Pin : 600049.